A new study published in the Cureus journal on December 7 found that 70% of deaths from the Pfizer vaccine in Japan were reported within 10 days of the jab.
A recent study found that in Japan, around 70% of individuals who died after getting the Pfizer COVID-19 vaccine passed away within the first 10 days of the injection.
The peer-reviewed Japanese study examined the relationship between the Pfizer COVID-19 immunization and mortality within ten days of vaccination, and it was published in the Cureus journal on December 7.
With Day 1 serving as the vaccination date, the risk period was defined as the first 10 days following vaccination, and the control period as the next 11 to 180 days following immunization.
Two groups were included in the analysis: Group 1 consisted of adults 65 years of age and older, while Group 2 included people 64 years of age and younger.
Subscribe to GreatGameIndia
Six62 men and 649 women made up Group 1, which the researcher found to have 1,311 deaths. The team found 247 deaths in Group 2, of which 155 were male and 92 were female.
“The percentage of reported cases that experienced death within 10 days after vaccination was 71 percent in Group 1 and 70 percent in Group 2,” said the study results.
In Group 1, during the first ten days following immunization, a greater number of women than males passed away from various illnesses. More male deaths were reported after the ten days.
The second day after vaccination saw the greatest number of deaths, followed by the third and fourth days.
Apart from “unexplained deaths,” ischemic heart disease accounted for the majority of deaths in this group with 119 deaths, followed by heart failure with 92 and aspiration pneumonia/asphyxia with 72. Of the 239 cases of unexplained death, eight involved autopsies.
During the first 10 days of immunization in Group 2, men died from a variety of medical illnesses at a rate more than twice that of women. Men’s overall death rates after the first 10 days were only marginally higher.
The third day had the greatest number of post-vaccination deaths, with the fourth, second, and fifth days following suit.
Following “unexplained deaths,” ischemic heart disease accounted for the greatest number of deaths in this group with 27, followed by cardiac arrhythmias with 24, subarachnoid hemorrhage with 20, and myocarditis/pericarditis with 17. There were 51 unexplained deaths; nine of them had autopsies.
During the “risk period,” myocarditis/pericarditis caused a disproportionate number of male and female deaths—eight men perished compared to just one woman. Nine men died of heart failure and only two women did as well.
“Some myocarditis/pericarditis cases may be included within the unexplained deaths category. Myocarditis is a complication of vaccination, especially in young adults and adolescent males,” said the study.
“Thought to be the high number of myocarditis/pericarditis deaths including undiagnosed cases” is one factor that may have contributed to the greater frequency of male deaths within the first 10 days.
Heart arrhythmias, aortic aneurysm/dissection, cerebral infarction, intracerebral hemorrhage, subarachnoid hemorrhage, respiratory failure, interstitial lung diseases, pulmonary embolism, pneumonia, sepsis, anaphylaxis, thrombocytopenia, and marasmus were the other reasons of mortality for both groups.
To put it briefly, a greater number of older Japanese women and men under 64 had an increased chance of passing away during the first 10 days after receiving the Pfizer immunization.
Male–Female Differences, Study Limitations
Yasusi Suzumura, the author, divided the total number of males by the total number of females and multiplied the result by 100 to get the sex ratios for all-cause fatalities and each outcome. In other words, the number of male deaths increases with the sex ratio.
The sex ratio of the study was impacted by the author’s discovery of significant disparities between the number of male and female deaths in both categories.
“If there is no effect on the occurrence of death, there should be no difference in sex ratios by period. Thus, this finding indicates that vaccination may influence the occurrence of death during the risk period and might be associated with death,” the study stated.
The Ministry of Health, Labour, and Welfare (MHLW) of Japan provided the study’s death data.
Particularly, cases that were reported between February 17, 2021, and March 12, 2023, and solely involved the BNT162b2 (Pfizer-BioNTech) mRNA vaccine were considered.
The report makes no explicit connection between the immunizations and the deaths. “The results indicate that the BNT162b2 mRNA vaccination may influence the occurrence of death during the risk period,” according to the research.
The study’s shortcomings were highlighted by the author, who also noted that the study did not take into account the immunization’s effects after 11 days and that the number of days from vaccination to death may vary depending on treatment.
In addition, the author claimed that only a small number of physicians could have completed the sex-based reporting and that the study was limited to fatalities following immunization, making it impossible to determine the mortality rates.
Because of the small sample size of the study, it should be “carefully” interpreted. Lastly, since not all deaths reported to the MHLW were associated with vaccinations, it is important to interpret the analysis results cautiously. The recorded deaths may include incidental deaths.
Since the majority of those receiving vaccinations are healthy, the study’s author emphasized that vaccines ought to be of “higher level of safety than pharmaceuticals used for treatment and should have an exceptionally low vaccination mortality rate.”
Therefore, statistical techniques must be used to analyze vaccine safety even in cases when the immunization death rate is abnormally low.
According to the study, it is challenging to distinguish between vaccine-related and incidental post-vaccination deaths at this time. However, the author came to the conclusion that this method can provide insightful information on evaluating vaccine safety.
‘Similar to Vaccine Deaths in US’
The data on “COVID-19 vaccination and death in Japan is very similar to vaccine deaths in US/Domestic cases in VAERS,” according to a Dec. 9 X post by cardiologist Dr. Peter McCullough, provided commentary on the study. “Strongly suggests causation for approximately 1150 recorded immediate deaths.”
Up until September 29, 2023, VAERS has recorded 18,188 deaths linked to the COVID-19 immunization, 1,150 of which happened on the day of the shot.
Furthermore, there were reports of 2,040 miscarriages, 9,053 heart attacks, 17,433 permanent impairments, 5,057 cases of myocarditis/pericarditis, and 36,184 severe allergic responses.
The Japanese study on X was also shared by the Association of American Physicians and Surgeons.
The study’s author made it clear that they have gotten “no financial support” for the work they submitted from any organizations.
Numerous other research have also connected COVID-19 vaccinations to increased chances of death. The distribution of COVID-19 vaccines was found to increase all-cause mortality in 17 of the countries examined, according to a report released on September 17 by Correlation Research in the Public Interest.
Nine of these 17 countries saw no discernible increase in fatalities after the WHO declared a pandemic in March 2020. Only after the immunization campaign did excess deaths start to occur.
January and February 2022 saw previously unheard-of highs in all-cause mortality in 15 of the 17 countries, which either accompanied or followed the introduction of booster shots.
According to the report, there were 1.74 million unnecessary deaths in the 17 countries over the vaccine period, or around one for every 800 doses.
The world’s first self-amplifying mRNA COVID-19 vaccine has been approved in Japan, although the vaccine’s maker has not released any safety or effectiveness information.
Because it produces more spike proteins in the human body than the current version, the most recent mRNA vaccination is even more effective than the current one.